Orchard Therapeutics plc
ORTXDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001748907
Orchard Therapeutics plc was delisted in 2024; its insiders filed their last Form 4 on Jan 24, 2024; 47 institutions reported holding it in 13F filings for Q4 2023, worth $122.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Orchard Therapeutics plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Orchard Therapeutics plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Geraghty James A | Director | 0 | Jan 24, 2024 | 0 |
| Thomas Frank E | See Remarks | 0 | Jan 24, 2024 | 0 |
| Rowland Charles A Jr | Director | 0 | Jan 24, 2024 | 0 |
| Altschuler Steven | Director | – | Jan 24, 2024 | 0 |
| Curnutte John T | Director | – | Jan 24, 2024 | 0 |
| Secor Alicia | Director | – | Jan 24, 2024 | 0 |
| Beck Joanne T. | Director | 0 | Jan 24, 2024 | 0 |
| Dunoyer Marc | Director | 0 | Jan 24, 2024 | 0 |
| Gaspar Bobby | Chief Executive Officer | 0 | Jan 24, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Gaspar BobbyChief Executive Officer | PPurchase | +15.0K | $0.74 | +$11.1K | +4.3%366.2K after | |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Thomas Frank ESee Remarks | PPurchase | +10.0K | $0.75 | +$7.50K | +23.8%52.1K after |